Illuccix, a preparation kit for injectable Ga-68, has been approved to select patients for radioligand therapy before taxane ...

Oncology nurses can help patients understand this novel mechanism of action and its potential as a treatment option.

Video content above is prompted by the following: This segment introduces a comprehensive case study of a 46-year-old graphic designer diagnosed with stage IV NSCLC harboring an EGFR exon 19 deletion ...

The combination of relacorilant and nab-paclitaxel improved survival in platinum-resistant ovarian cancer following a break ...

Dato-DXd was granted accelerated approval for use in adults with EGFR-mutated NSCLC after EGFR-targeted therapy and platinum-based chemotherapy. The FDA has granted acceleratedapproval to the antibody ...

The novel MEK inhibitor atebimetinib plus chemo showed early signs of survival benefit in first-line treatment of patients with pancreatic cancer. First-line treatment with the oral, novel MEK ...

Per ODAC and CHMP recommendations, subcutaneous daratumumab may become the first approved treatment for smoldering myeloma.

The BCI and patient goals help oncology nurses counsel patients on endocrine therapy use after 5 years, per Michelle Kirschner RN, MSN, ACNP, APRN-BC.

Durvalumab (Imfinzi) is a PD-L1–blocking antibody that has 3 indications for non–small cell lung cancer (NSCLC). February ...

Biomarker data from CodeBreaK 300 suggest DNA and RTK pathway alterations may underlie resistance to sotorasib plus ...

The FDA has approved tafasitamab in combination with lenalidomide and rituximab for adults with relapsed/refractory ...

Because of the selection of CDK4/6 inhibitors now available in the first-line setting for patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer, providers now have the ...